D. Haydar Laboratory

About the Lab

The D. Haydar Laboratory works on designing effective, long-lasting, and safe cellular immunotherapies for childhood brain cancer. CAR T cell therapy is an innovative technology based on adoptive transfer of antigen-specific T cells engineered to elicit a clinically effective and specific immune response against tumor cells. Our aim is to investigate mechanisms responsible for the lack of CAR T cell efficacy in pediatric brain tumors using cutting-edge technologies and innovative animal models that recapitulate human disease and barriers for adoptive immunotherapies.

Lab Focus Areas
Cell Enhancement and Technologies for Immunotherapy

Neuro-Oncology

Tumor Immunology
Partnerships
Institute for Biomedical Sciences (IBS) Program, George Washington University School of Medicine and Health Sciences
Howard University Graduate School
Contact
Dalia Haydar, Pharm.D., Ph.D. D. Haydar Laboratory [email protected] 202-476-1035

Featured Publications

cBAF complex components and MYC cooperate early in CD8+ T cell fate
Guo, Ao, et al. Nature 607.7917:135-141 (2022)
T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges
Haydar, Dalia, et al. Frontiers in Oncology 11 (2021)
Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery
Haydar, Dalia, et al. Neuro-Oncology 23.6:999-1011 (2021)
Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T cell effector differentiation
Zebley, Caitlin C., et al. Cell reports 37.2:109796 (2021)
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
Prinzing, Brooke, et al.  Science Translational Medicine 13.620:eabh0272 (2021)
Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR. CD28ζ T cells
Nguyen, Phuong, et al. Molecular Therapy-Oncolytics 18:202-214 (2020)
Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
Land, Craig A., et al. Journal of translational medicine 18.1:1-13 (2020)

D. Haydar Laboratory

About the Lab

Featured Publications

cBAF complex components and MYC cooperate early in CD8+ T cell fate

T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges

Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery

Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T cell effector differentiation

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR. CD28ζ T cells

Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight

Related News

Research, Education & Innovation Week 2025

Regional powerhouse: Cell and Gene therapy leaders from mid-Atlantic forge connections

Honor bestowed on AeRang Kim, M.D., Ph.D.